Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Molecular cancer·2026

Same author

Reconstruction from multi-planar MRI with foundation models for uterine fibroid analysis.

NPJ digital medicine·2026

Same author

Complement factor H (CFH), an immune factor enhances osteoblast differentiation and correlates with bone density.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Same author

Unidirectional spectral singularity lasing in a defective atomic lattice.

Optics express·2026

Same author

Adipokine Nesfatin-1 Mediates Endothelial Dysfunction by Suppressing <i>MEF2B</i>/<i>BMPR1A</i> During Pulmonary Vascular Remodeling.

Journal of the American Heart Association·2026

Same author

Navigating tipping points: A complex systems framework for anticipating lake ecosystem collapse.

Fundamental research·2026

Same journal

Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases.

Cell death & disease·2026

Same journal

The alternative NF-κB RelB subunit is a novel critical sensor of lipid metabolism to promote tumor development.

Cell death & disease·2026

Same journal

Activation of KIT signaling promotes early tumorigenesis through the AP-1 pathway in APC/TP53 double-knockout human colon organoids.

Cell death & disease·2026

Same journal

Rethinking LPCAT3 roles in human disease: broadening perspectives beyond ferroptosis.

Cell death & disease·2026

Same journal

GDPPH1 induces cell cycle arrest by downregulation of CDK4/Cyclin D1 via the m<sup>6</sup>A-METTL14-YTHDF2 axis, attenuating glioblastoma progression.

Cell death & disease·2026

Same journal

Tumor-derived PCSK9-enriched exosomes reprogram adipocytes to drive metabolic dysregulation and immune evasion in triple-negative breast cancer.

Cell death & disease·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

GATOR1 complex controls cisplatin sensitivity.

Zhenrui Pan^1,2, Hanxiao Zhang¹, Xia Xiao¹

¹CNRS UMR9018, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Cell Death & Disease

|December 30, 2025

Summary

This summary is machine-generated.

The GATOR1 complex, not just NPRL2, is crucial for cisplatin resistance in cancers. Deleting GATOR1 components increases resistance, while overexpression restores sensitivity, offering new therapeutic targets for chemotherapy resistance.

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Area of Science:

Oncology
Molecular Biology
Biochemistry

Background:

Cisplatin is a key chemotherapy for epithelial cancers, but drug resistance is a major obstacle.
Low NPRL2 expression was previously linked to cisplatin resistance.
NPRL2, NPRL3, and DEPDC5 form the GATOR1 complex, regulating mTORC1, which is often dysregulated in cisplatin-resistant cancers.

Purpose of the Study:

To investigate the role of the GATOR1 complex in cisplatin resistance beyond NPRL2.
To compare intrinsic and acquired cisplatin resistance models.
To identify molecular mechanisms underlying GATOR1-mediated cisplatin resistance.

Main Methods:

Utilized BEAS-2B cells with GATOR1 deletions as an intrinsic resistance model.
Employed cisplatin-resistant non-small cell lung cancer cell lines (A549, H460, H1975) for acquired resistance.
Analyzed transporter expression (ATP7A, CTR2, LRRC8A), DNA damage response, mTORC1 activity, and performed transcriptomic analysis.

Main Results:

Deletion of any GATOR1 component confers cisplatin resistance; overexpression restores sensitivity.
GATOR1 deletion upregulates cisplatin efflux (ATP7A) and downregulates influx (CTR2, LRRC8A) transporters.
Cells with GATOR1 deletions show increased DNA damage response and mTORC1 activity, hindering cisplatin-DNA adduct formation.

Conclusions:

The GATOR1 complex, not solely NPRL2, plays a significant role in both intrinsic and acquired cisplatin resistance.
Altering GATOR1 component expression or inhibiting mTORC1 can modulate cisplatin sensitivity.
GATOR1's novel function in chemoresistance warrants consideration for developing new therapeutic strategies against cisplatin resistance.